Vertex Pharmaceuticals, Inc.
VRTX
Market Cap$127.03B
Close$
Earnings Call Q2 2024
August 1, 2024 - AI Summary
Vertex Pharmaceuticals reported strong financial results for the second quarter of 2024, with revenue increasing by 6% year-over-year to $2.65 billion.
The company raised its full-year product revenue guidance to a range of $10.65 billion to $10.85 billion, representing 9% growth at the midpoint.
Vertex continues to see strong demand for its cystic fibrosis (CF) treatments, reaching more patients and expanding into younger age groups. The upcoming launch of the Vanzacaftor Triple combination is expected to drive further growth in CF.
Exclusive for Stockcircle Pro members
Sign up
$851.37
80.8% upside
Current Fair Value
80.8% upsideUndervalued by 80.8% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $127.03 Billion |
|---|---|
| Enterprise Value | $127.96 Billion |
| Dividend Yield | $0.0 (0.0%) |
| Earnings per Share | $15.42 |
| Beta | 0.58 |
| Outstanding Shares | 258,053,387 |
Return
| Return on Equity | - |
|---|---|
| Return on Assets | - |
| Return on Invested Capital | - |
Valuation & Multiples
| P/E Ratio | 31.6 |
|---|---|
| PEG | -6.42 |
| Price to Sales | 11.77 |
| Price to Book Ratio | 7.85 |
| Enterprise Value to Revenue | 12.38 |
| Enterprise Value to EBIT | -335.16 |
| Enterprise Value to Net Income | -262 |
| Total Debt to Enterprise | 0.01 |
| Debt to Equity | 0.05 |
Revenue Sources
No data
Insider Trades
ESG Score
No data
About Vertex Pharmaceuticals, Inc.
CEO: Jeffrey Leiden